André Tonetto1, Pablo Walker Lago1, Márcia Borba1, Vinícius Rosa2. 1. University of Passo Fundo, School of Dentistry, Passo Fundo, Brazil. 2. Faculty of Dentistry, Oral Sciences, National University of Singapore, 11 Lower Kent Ridge Road, Singapore, 119083, Singapore. denvr@nus.edu.sg.
Abstract
OBJECTIVES: The objective of this study was to evaluate the use of a chondroitin sulfate and glycosaminoglycan-based chrondro-osseous regenerative compound (CORC) with different local treatments for bone regeneration in dehiscence defects. The hypothesis is that CORC can enhance bone regeneration with or without local treatment. MATERIALS AND METHODS: Twelve mongrel dogs received four implants each in the right femur. Bony defects (4-mm height × 4-mm width) were created and locally treated as follows: reabsorbable membrane (Mem), hidroxyapatite (HA), hydroxyapatite covered with membrane (HA+Mem), or left untreated (Con). Six dogs received one pill of the CORC daily. After 90 days, the implants were retrieved, and histological sections were obtained. The height of bone formation, new bone area (NBA), and bone to implant contact (BIC) within the threads were evaluated to assess the effects of the use of CORC to promote bone regeneration in the defects. Results were statistically analyzed using ANOVA and Tukey's test with 5% significance level. RESULTS: CORC was not capable to increase the height of bone formation, NBA, and BIC. When the local treatments were analyzed regardless of the use of CORC, HA+Mem and Ha presented higher BIC and height of bone formation. There was no difference for NBA among the local treatments. CONCLUSIONS: The hypothesis was rejected since the use of CORC has not increased any of the parameters evaluated. CLINICAL RELEVANCE: Dehiscence-like defects can compromise soft tissue support and result in loss of periodontal health and implants. Hydroxyapatite can induce bone regeneration in the defects created. CORC in the formulation used in this study did not promote further bone regeneration in dehiscence-like defects.
OBJECTIVES: The objective of this study was to evaluate the use of a chondroitin sulfate and glycosaminoglycan-based chrondro-osseous regenerative compound (CORC) with different local treatments for bone regeneration in dehiscence defects. The hypothesis is that CORC can enhance bone regeneration with or without local treatment. MATERIALS AND METHODS: Twelve mongrel dogs received four implants each in the right femur. Bony defects (4-mm height × 4-mm width) were created and locally treated as follows: reabsorbable membrane (Mem), hidroxyapatite (HA), hydroxyapatite covered with membrane (HA+Mem), or left untreated (Con). Six dogs received one pill of the CORC daily. After 90 days, the implants were retrieved, and histological sections were obtained. The height of bone formation, new bone area (NBA), and bone to implant contact (BIC) within the threads were evaluated to assess the effects of the use of CORC to promote bone regeneration in the defects. Results were statistically analyzed using ANOVA and Tukey's test with 5% significance level. RESULTS: CORC was not capable to increase the height of bone formation, NBA, and BIC. When the local treatments were analyzed regardless of the use of CORC, HA+Mem and Ha presented higher BIC and height of bone formation. There was no difference for NBA among the local treatments. CONCLUSIONS: The hypothesis was rejected since the use of CORC has not increased any of the parameters evaluated. CLINICAL RELEVANCE: Dehiscence-like defects can compromise soft tissue support and result in loss of periodontal health and implants. Hydroxyapatite can induce bone regeneration in the defects created. CORC in the formulation used in this study did not promote further bone regeneration in dehiscence-like defects.
Entities:
Keywords:
Bone formation; Chondroitin sulfate; Glycosaminoglycan; Guided bone regeneration; Hydroxyapatite; Membrane; Titanium
Authors: F Schwarz; M Herten; D Ferrari; M Wieland; L Schmitz; E Engelhardt; J Becker Journal: Int J Oral Maxillofac Surg Date: 2007-09-10 Impact factor: 2.789
Authors: Jane B Lian; Amjad Javed; S Kaleem Zaidi; Christopher Lengner; Martin Montecino; Andre J van Wijnen; Janet L Stein; Gary S Stein Journal: Crit Rev Eukaryot Gene Expr Date: 2004 Impact factor: 1.807